Halozyme to Report Second Quarter 2025 Financial and Operating Results
Rhea-AI Summary
Halozyme Therapeutics (NASDAQ: HALO) has scheduled the release of its second quarter 2025 financial and operating results for Tuesday, August 5, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.
Investors can access the conference call through pre-registration and join the live webcast through Halozyme's investor relations website. A replay will also be available on the corporate website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, HALO gained 2.90%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2025-financial-and-operating-results-302510433.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (NASDAQ:HALO) report Q2 2025 earnings?
What time is Halozyme's Q2 2025 earnings conference call?
How can investors access Halozyme's Q2 2025 earnings call?
Will there be a replay available of Halozyme's Q2 2025 earnings call?
